Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: a Mendelian randomization study

Mark Gormley[1,2,3]*, James Yarmolinsky[1,3], Tom Dudding[1,2,3], Kimberley Burrows[1,3], Richard M Martin[1,3,4], Steven Thomas[2,4], Jessica Tyrrell[5], Paul Brennan[6], Miranda Pring[2], Stefania Boccia[7,8], Andrew F Olshan[9], Brenda Diergaarde[10], Rayjean J. Hung[11,12], Geoffrey Liu[12,13], Danny Legge[14], Eloiza H Tajara[15], Patricia Severino [16], Martin Lacko[17], Andrew R Ness[4], George Davey Smith[1,3], Emma E Vincent[1,3,14&], Rebecca C Richmond[1,3&]

[1] MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

[2] Bristol Dental Hospital and School, University of Bristol, Bristol, UK.

[3] Department of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

[4] National Institute for Health Research Bristol Biomedical Research Centre at the University Hospitals Bristol and Weston NHS Foundation Trust, University of Bristol, Bristol, UK.

[5] University of Exeter Medical School, RILD Building, RD&E Hospital, Exeter, UK.

[6] Genetic Epidemiology Group, World Health Organization, International Agency for Research on Cancer, Lyon, France.

[7] Sezione di Igiene, Istituto di Sanità Pubblica, Università Cattolica del Sacro Cuore, Roma, Italy.

[8] Department of Woman and Child Health and Public Health, Public Health Area, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.

[9] Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, US.

[10] Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, and UPMC Hillman Cancer Center, Pittsburgh, US.

[11] Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada.

[12] Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.

[13] Princess Margaret Cancer Centre, Toronto Canada.

[14] School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.

[15] School of Medicine of São José do Rio Preto, São Paulo, Brazil.

[16] Albert Einstein Research and Education Institute, Hospital Israelita Albert Einstein, São Paulo, Brazil.

[17] Department of Otorhinolaryngology and Head and Neck Surgery, Research Institute GROW, Maastricht University Medical Center, Maastricht, The Netherlands.

Corresponding author

* Email: mark.gormley@bristol.ac.uk

Author contributions

[&] These authors also contributed equally to this work.

E.E.V. and R.C.R. are joint senior authors. M.G., R.C.R. and E.E.V. conceived the study and M.G. carried out data curation and formal analysis. K.B. performed the GWAS of head and neck cancer in UK Biobank. Head and neck cancer summary genetic data was obtained through multiple collaborations from studies lead and curated by A.R.N., S.T., A.F.O., B.D., R.J.H., G.L., M.L., E.T., S.B. and P.B. Expert guidance on MR methodology was provided by R.C.R., J.Y., G.D.S. and R.M.M., R.C.R., G.D.S, J.T., S.T., P.B., R.M.M. and A.R.N. provided expertise on both observational and genetic epidemiological methodology and analysis. The initial manuscript was drafted by M.G., R.C.R. and E.E.V. All authors (M.G., J.Y., T.D., K.B., R.M.M., S.T., J.T., A.R.N., P.B., M.P., S.B., A.F.O., B.D, R.J.H., G.L., D.L., E.H.T., P.S., M.L., A.R.N., G.D.S., E.E.V. and R.C.R.) contributed to the interpretation of the results, editing and critical revision of the manuscript. M.G.'s PhD supervisory team includes R.C.R., E.E.V., J.T., A.R.N and G.D.S.

Abbreviations: HNSCC, head and neck squamous cell carcinoma; OC, oral cancer; OPC, oropharyngeal cancer; HPV, human papilloma virus; MR, Mendelian randomization; GWAS, genome-wide association study; SNP, single nucleotide polymorphism; PCA, principal component analysis; NOME, no measurement error; SIMEX, simulation extrapolation; MR-PRESSO, Mendelian Randomization Pleiotropy RESidual Sum and Outlier; GAME-ON, Genetic Associations and Mechanisms in Oncology; HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase; NPC1L1, NPC1 like intracellular cholesterol transporter 1; CETP, cholesteryl ester transfer protein; PCSK9, proprotein convertase subtilisin/kexin type 9; LDLR, low-density lipoprotein receptor; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; LD, linkage disequilibrium; OR, odds ratio; se, standard error; IVW, inverse variance weighted; CI, confidence intervals; P, *p*-value.

Abstract

Introduction

Head and neck squamous cell carcinoma (HNSCC), which includes cancers of the oral cavity and oropharynx, is a cause of substantial global morbidity and mortality. Strategies to reduce disease burden include discovery of novel therapies and repurposing of existing drugs. Statins are commonly prescribed for lowering circulating cholesterol by inhibiting HMG-CoA reductase (HMGCR). Results from some observational studies suggest that statin use may reduce HNSCC risk. We appraised the relationship of genetically-proxied cholesterol-lowering drug targets and other circulating lipid traits with oral (OC) and oropharyngeal (OPC) cancer risk.

Methods and findings

We conducted two-sample Mendelian randomization (MR). For the primary analysis, germline genetic variants in *HMGCR*, *NPC1L1*, *CETP, PCSK9* and *LDLR* were used to proxy the effect of low-density lipoprotein cholesterol (LDL-C) lowering therapies. In secondary analyses, variants were used to proxy circulating levels of other lipid traits in a genome-wide association study (GWAS) meta-analysis of 188,578 individuals. Both primary and secondary analyses aimed to estimate the downstream causal effect of cholesterol lowering therapies on OC and OPC risk.

The second sample for MR was taken from a GWAS of 6,034 OC and OPC cases and 6,585 controls (GAME-ON). Analyses were replicated in UK Biobank, using 839 OC and OPC

cases and 372,016 controls and the results of the GAME-ON and UK Biobank analyses combined in a fixed-effects meta-analysis.

We found limited evidence of a causal effect of genetically-proxied LDL-C lowering using HMGCR, NPC1L1, CETP or other circulating lipid traits on either OC or OPC risk. Genetically-proxied PCSK9 inhibition equivalent to a 1 mmol/L (38.7 mg/dL) reduction in LDL-C was associated with an increased risk of OC and OPC combined (OR 1.8 95%CI 1.2, 2.8, p= 9.31 $x10^{-05}$), with good concordance between GAME-ON and UK Biobank (I^2= 22%). Effects for PCSK9 appeared stronger in relation to OPC (OR 2.6 95%CI 1.4, 4.9) than OC (OR 1.4 95%CI 0.8, 2.4). LDLR variants, resulting in genetically-proxied reduction in LDL-C equivalent to a 1 mmol/L (38.7 mg/dL), reduced the risk of OC and OPC combined (OR 0.7, 95%CI 0.5, 1.0, p= 0.006). A series of pleiotropy-robust and outlier detection methods showed that pleiotropy did not bias our findings.

Conclusion

We found limited evidence for a role of cholesterol-lowering in OC and OPC risk, suggesting previous observational results may have been confounded. There was some evidence that genetically-proxied inhibition of PCSK9 increased risk, while lipid-lowering variants in LDLR, reduced risk of combined OC and OPC. This result suggests that the mechanisms of action of PCSK9 on OC and OPC risk may be independent of its cholesterol lowering effects, but further replication of this finding is required.

Author summary

Why was this study done?

- To determine if genetically-proxied cholesterol-lowering drugs (such as statins which target HMGCR) reduce oral and oropharyngeal cancer risk.
- To determine if genetically-proxied circulating lipid traits (e.g. low-density lipoprotein cholesterol) have a causal effect on oral and oropharyngeal cancer risk.

What did the researchers do and find?

- There was little evidence that genetically-proxied inhibition of HMGCR (target of statins), NPC1L1 (target of ezetimibe) and CETP (target of CETP inhibitors) influences oral or oropharyngeal cancer risk.
- There was little evidence of an effect of circulating lipid traits on oral or oropharyngeal cancer risk.
- There was some evidence that genetically-proxied inhibition of PCSK9 increases, while lipid-lowering variants in LDLR reduces oral and oropharyngeal cancer risk .

What do these findings mean?

- These findings suggest that the results of previous observational studies examining the effect of statins on oral and oropharyngeal risk may have been confounded.
- Given we found little evidence of an effect of other cholesterol lowering therapies, the mechanism of action of PCSK9 may be independent of cholesterol-lowering. Further replication of this finding in other head and neck cancer datasets is required.

143 **Introduction**

144

145 Head and neck squamous cell carcinoma (HNSCC), which includes cancers of the oral
146 cavity (OC) and oropharynx (OPC), is the sixth most common cancer in the world, with over
147 550,000 new cases and 300,000 deaths annually [1, 2]. Despite some modest improvements
148 in the treatment of HNSCC, survival ranges between 19 - 59% at 10 years [3] and recurrence
149 rates remain high [4]. Patients often undergo a combination of surgery, radiotherapy and
150 chemotherapy which can result in significant morbidity [5]. Established risk factors include
151 smoking, alcohol and human papilloma virus (HPV), the latter mainly linked with
152 oropharyngeal cancer [6, 7]. Given that in contemporary cohorts, around 70% of OPC cases
153 (versus <5% of OC cases) are HPV driven and often present in younger populations, oral and
154 oropharyngeal tumours are considered distinct disease entities, with different risk factor
155 profiles [8]. Despite smoking cessation, alcohol reduction measures and the implementation
156 of HPV vaccination in some areas, HNSCC remains a major global health problem [2]. Novel
157 strategies for prevention of HNSCC are required, in particular for those at high risk and one
158 approach is to identify novel risk factors which can be easily modified, for example by
159 repurposing existing drugs [9].

160

161 Statins are one of the most commonly prescribed medications worldwide. They are
162 prescribed to reduce levels of circulating total and low-density lipoprotein cholesterol (LDL-
163 C), with proven preventative and therapeutic effects in cardiovascular disease and a good
164 safety profile [10, 11]. Statins inhibit 3-hydroxy-3-methylglutaryl-coenzyme A reductase
165 (HMG-CoA reductase (HMGCR)), the rate-limiting enzyme in the mevalonate pathway,
166 responsible for cholesterol and steroid hormone synthesis [12]. Other clinically approved

drugs that target cholesterol metabolism via different mechanisms include ezetimibe (targeting Niemann-Pick C1-like protein (NPC1L1)) and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors such as evolocumab or alirocumab. These agents act by reducing the intestinal absorption of cholesterol or by enhancing uptake of LDL-C through increased cellular membrane expression of the LDL-receptor (LDLR), respectively. Conversely, cholesteryl ester transfer protein inhibitors (CETP) substantially increase levels of high-density lipoprotein cholesterol (HDL-C), lower levels of LDL-C and enhance reverse cholesterol transport [13].

Cholesterol is vital for a variety of key cellular functions, including membrane integrity, signalling, protein synthesis and cell cycle progression. Therefore, modulation of cholesterol synthesis has the potential to influence several hallmarks of tumourigenesis including cell migration and proliferation [14]. In an experimental study, mice given oral daily doses of simvastatin two weeks prior to subcutaneous injection of FaDu (HPV-negative hypopharyngeal tumour cells), showed a significant reduction in tumour growth. This study was designed to mimic a clinical scenario where patients who present with a tumour may have been taking the medication prior to tumour initiation [15], and suggested that simvastatin antagonises tumour metabolic reprogramming, another important hallmark of cancer [15]. Mechanistic support for the role of LDL-C lowering in cancer development comes largely from the fact that lipids are themselves major cell membrane components essential for cell division and maintaining tissue integrity. Changes in lipid levels have been reported associated with tumour development [16, 17].

However, the evidence that cholesterol-lowering drugs may reduce the risk of head and neck cancer is limited. Some observational studies report an inverse association of taking statins with both head and neck cancer risk and survival [14, 18], but others indicate little evidence of any effect [19]. Observational studies are not randomised and are susceptible to reverse causality and/or confounding [19]. Mendelian randomization (MR) is an approach that uses germline genetic proxies (referred to as instruments) to help appraise causal effects of potentially modifiable extrinsic exposures or intrinsic traits with disease [20-22]. It has also been used to estimate therapeutic potential by investigating genetic variation at drug targets [23]. Numerous single nucleotide polymorphisms (SNPs) are associated with lower levels of circulating LDL-C [24, 25] and inheriting an LDL-C lowering allele has been proposed to be analogous to being assigned life-long treatment with a cholesterol lowering drug [26]. In this way, germline genetic variants may serve as proxies for exposure to potential pharmacological agents which are less likely than observational measures to be subject to reverse causation or confounding. Genetic proxies can therefore be used to predict both the likely beneficial and adverse effects of long-term modulation of the drug targets on disease.

MR has previously demonstrated the protective effect of cholesterol-lowering drugs on cardiovascular disease risk [27] , but also that inhibition of HMGCR and PCSK9 may have an adverse effect on diabetes risk [28]. Of relevance to cancer, some recent MR studies have shown that genetically-proxied inhibition of HMGCR may be protective against overall cancer [29] and epithelial ovarian cancer [30] risk. Our aim was to use MR to appraise the causal nature and mechanistic basis of the relationship between cholesterol-lowering and

risk of oral and oropharyngeal cancer by investigating germline variation in HMGCR, NPC1L1, CETP, PCSK9 and LDLR, and other related lipid traits such as circulating LDL-C.

Methods

Identifying cholesterol-lowering genetic instruments. For the primary analysis, SNPs in *HMGCR*, *NPC1L1*, *CETP, PCSK9* and *LDLR* were used to proxy the effect of lipid-lowering therapies and to estimate the downstream effect of manipulating these targets on OC and OPC risk. SNPs were identified within 100 kb on either side of the target gene (*HMGCR*, *NPC1L1*, *CETP, PCSK9* and *LDLR)* that were associated with LDL-C levels. Variants were robustly associated with LDL-C in a meta-analysis of genome-wide association studies (GWAS) involving 188,578 individuals primarily (96%) of European ancestry in the Global Lipids Genetic Consortium (GLGC) [25]. Linkage disequilibrium (LD) (r^2) was evaluated to check the overlap between variants using LDmatrix (4.0 Release) [31]. Proxy SNPs were permitted to be in weak LD (r^2 <0.2) with each other, to increase the proportion of variance explained in each respective drug target therefore maximising instrument strength. Multiple papers have used these genetic instruments at this threshold, to demonstrate causal effects in cardiovascular disease [13, 27, 32], diabetes [28] and ovarian cancer [30]. In secondary analyses, SNPs were used to proxy circulating levels of LDL-C, HDL-C, total triglyceride, total cholesterol, apolipoprotein A and B. Betas represented the change in lipid trait levels per copy of the effect allele. These SNPs were already independently (r^2 <0.001) associated with the respective traits in large GWAS which have been described previously [25, 33].

236 **Summary level genetic data on oral and oropharyngeal cancer from GAME-ON.**

237 We estimated the effects of the cholesterol-lowering genetic variants on risk of OC and OPC
238 using GWAS performed on 6,034 cases and 6,585 controls from 12 studies which were part
239 of the Genetic Associations and Mechanisms in Oncology (GAME-ON) Network [34]. The
240 study population included participants from Europe (45.3%), North America (43.9%) and
241 South America (10.8%). Cancer cases comprised the following the International
242 Classification of Diseases (ICD) codes: oral cavity (C02.0-C02.9, C03.0-C03.9, C04.0-C04.9,
243 C05.0-C06.9) oropharynx (C01.9, C02.4, C09.0-C10.9), hypopharynx (C13.0-C13.9),
244 overlapping (C14 and combination of other sites) and 25 cases with unknown ICD code
245 (other). A total of 954 individuals with cancers of hypopharynx, unknown code or
246 overlapping cancers were excluded. Genomic DNA isolated from blood or buccal cells was
247 genotyped at the Center for Inherited Disease Research (CIDR) using an Illumina OncoArray
248 custom designed for cancer studies by the OncoArray Consortium [35]. In GAME-ON, all
249 SNPs with a call rate of <95% were excluded. Given the ethnic heterogeneity of the study
250 population, the dataset was divided by geographical region and SNPs within each region
251 that showed deviation from Hardy-Weinberg Equilibrium (HWE) in controls ($p= <1 \times 10^{-7}$)
252 were excluded. Principal component analysis (PCA) was performed using approximately
253 10,000 common markers in low LD ($r^2 <0.004$), minor allele frequency (MAF) >0.05 and 139
254 population outliers were removed. Full details of the included studies, as well as the
255 genotyping and imputation performed, have been described previously [34, 36].

256

257 **Two-sample Mendelian randomization.** Two-sample MR was conducted using the
258 "TwoSampleMR" package in R (version 3.5.3), by integrating SNP associations for
259 cholesterol-lowering (sample 1) with those for OC and OPC in GAME-ON (sample 2). For

260 those SNPs instrumenting LDL-C lowering, we first extracted summary statistics for the
261 associations with OC and OPC from GAME-ON. We next performed harmonisation of the
262 direction of effects between the cholesterol-lowering exposures and outcome (OC or OPC)
263 where, for each variant, the allele designated the 'exposure allele' was associated with
264 lower LDL-C levels and palindromic SNPs were aligned when MAFs were <0.3 or were
265 otherwise excluded. In our primary analysis, four palindromic SNPs, one in *HMGCR*
266 (rs2006760), the other in *PCSK9* (rs2149041) and two in *CETP* (rs5880, rs9929488) were
267 removed. In the secondary analysis with other lipid traits, 11 palindromic SNPs (rs1936800,
268 rs2288912, rs7112577, rs964184, rs150617279, rs1883711, rs4722043, rs2156552,
269 rs2954029, rs581080, rs7534572) were removed.
270
271 Individual effect-estimates for each SNP were calculated using the Wald ratio, by
272 dividing the SNP-outcome association by the SNP-exposure association. Multiple SNPs were
273 then combined into multi-allelic instruments using the random-effects inverse-variance
274 weighted (IVW) meta-analysis method, for each of the genes *HMGCR*, *NPC1L1, CETP, PCSK9*
275 and *LDLR*. This meta-analysis was undertaken to increase the proportion of variance in drug
276 targets and LDL-C lowering explained by each instrument, and thus improve statistical
277 power and the precision of our estimates [37]. The analysis produced an estimate of the
278 effect of the risk factor on OC and OPC risk. As the instruments for *HMGCR*, *NPC1L1, CETP,*
279 *PCSK9* and *LDLR* were in weak LD (r^2 <0.2), we accounted for this correlation between SNPs
280 in the primary analysis using LDlink (4.0 Release) which employs Phase 3 (Version 5) of the
281 1000 Genomes Project and variant rs numbers based on dbSNP. Correlation matrices were
282 inserted as an MRInput object [31], resulting in MR methods which altered the weightings
283 for correlated SNPs. For circulating lipid traits, a more stringent r^2 <0.001 was already

284 applied in the initial GWAS [25], so we did not account further for correlation in the
285 secondary analysis. We computed odds ratios (OR) which represent the change in odds of
286 oral and oropharyngeal squamous cell carcinoma per genetically-proxied inhibition of the
287 drug target, equivalent to a 1 mg/dl decrease in LDL-C. The OR was scaled to be per 1
288 mmol/L decrease by dividing the LDL-C lowering effect (beta) and standard error (se)
289 measured in mg/dL by 38.7 [30]. The betas and standard errors for *HMGCR*, *NPC1L1*, *CETP*,
290 *PCSK9* and *LDLR* SNPs were also converted to reflect the cholesterol-lowering effect, given
291 the "TwoSampleMR" package preference to automatically change these into a positive
292 direction of effect (i.e. lipid increasing). The correct direction of effect was checked using a
293 positive control of coronary heart disease from the CARDIoGRAM GWAS data [38]. MR was
294 also used to examine the effect of circulating levels of LDL-C, HDL-C, total triglyceride, total
295 cholesterol, apolipoprotein A and B levels directly with OC and OPC cancer risk. The ORs in
296 this analysis represent the change in odds of oral or oropharyngeal squamous cell
297 carcinoma, per SD unit increase in lipid trait.
298
299 The IVW method can provide an unbiased effect estimate in the absence of
300 horizontal pleiotropy or when horizontal pleiotropy is balanced [39]. We therefore
301 performed sensitivity analyses to evaluate the potential for unbalanced horizontal
302 pleiotropy, where genetic variants influence two or more traits through independent
303 biological pathways. To ensure the genetic instrument was associated with the instrument it
304 was proxying, estimates of the proportion of variance in each risk factor explained by the
305 instrument (R^2) and F-statistics were generated. An F-statistic of <10 is indicative of a weak
306 instrument which may be subject to weak instrument bias. To account for directional
307 pleiotropy, we compared the IVW results with three MR sensitivity analyses, which each

make different assumptions: MR Egger [40], weighted median [41] and weighted mode [42]. While these three methods are best used when genetic instruments consist of a large numbers of independent SNPs, since r^2 values between SNPs in our instruments were low (r^2 <0.2), we a-priori decided to include them, with a further sensitivity analysis to account for correlation in the MR Egger analysis. The weighted median stipulates that at least 50% of the weight in the analysis stems from variants that are valid instruments [41], while the weighted mode requires that the largest subset of instruments which identify the same causal effect to be valid instruments [42]. MR-Egger can provide unbiased estimates even when all SNPs in an instrument violate the exclusion restriction assumption (i.e. affect the outcome by means other than via the risk factor of interest). However, there must be negligible measurement error (NOME) [43] in the genetic instrument and the InSIDE (Instrument Strength Independent of Direct Effect) assumption must be satisfied [40]. Where there was evidence of violation of the NOME assumption, this was assessed using the I^2 statistic and MR-Egger was performed with simulation extrapolation (SIMEX) correction [43]. To further assess the robustness of findings, we examined evidence of heterogeneity in the individual SNP estimates using the Cochran Q-statistic, which may indicate the presence of invalid instruments (e.g. due to horizontal pleiotropy) [44]. Scatter and leave-one-out plots were produced to evaluate influential outliers and MR-PRESSO (Mendelian Randomization Pleiotropy RESidual Sum and Outlier) was used to detect and correct for potential outliers (where Q-statistic $p < 0.05$) [45].

329 **Stratification by cancer subsite.** Given the difference in established aetiology (i.e. smoking,
330 alcohol and HPV) at each HNSCC subsite [6], we performed MR analyses with stratification
331 by cancer subsite to evaluate potential heterogeneity in effects. For this, we used GWAS
332 summary data on a subset of 2,641 OPC cases and 2,990 OC cases from the 6,034 HNSCC
333 cases and the 6,585 common controls in the GAME-ON GWAS [34].
334
335 **Replication in UK Biobank.** UK Biobank data was used as a replication dataset for primary
336 analyses. A GWAS was performed on 839 combined OC and OPC cases and 372,016 controls,
337 with two further stratified GWAS for OC (n= 357) and OPC (n= 494). UK Biobank is a large
338 population-based cohort study that recruited over 500,000 men and women aged between
339 37 and 73 years between 2006 and 2010 throughout the UK. It received ethical approval
340 from the National Health Service North West Centre for Research Ethics Committee
341 (reference: 11/NW/0382). Details of genotyping quality control, phasing and imputation are
342 described elsewhere [46]. Participant records are linked to cancer registry data and HNSCC
343 was grouped using the same ICD-codes as described above. Squamous cell carcinoma cases
344 were identified using histology codes 8070 – 8078. All GWAS analyses were adjusted for the
345 top 10 genetic principal components, age, and sex. Primary MR analyses as described above
346 in GAME-ON were repeated in UK Biobank data.
347
348 **Meta-analysis of results.** We performed both fixed-effects and random-effects meta-
349 analysis of the MR estimates in GAME-ON and UK Biobank using the R package 'meta'.
350 However, we focus more on the fixed-effects estimates since we assume that the causal
351 effect is constant between the studies [47]. Heterogeneity between study populations was
352 assessed using I^2 statistic [48].

353

354 **Results**

355

356 **Primary analysis in GAME-ON.** In total, 5 SNPs in *HMGCR* (rs12916, rs17238484, rs5909,
357 rs2303152, rs10066707) were used to proxy HMG-CoA reductase inhibition (statins); 5 SNPs
358 in *NPC1L1* (rs217386, rs2073547, rs7791240, rs10234070, rs2300414) proxied NPC1L1
359 inhibition (ezetimibe); 6 SNPs in *CETP* (rs9989419, rs12708967, rs3764261, rs1800775,
360 rs1864163, rs289714) proxied CETP inhibition; 6 SNPs in *PCSK9* (rs11206510, rs2479409,
361 rs2479394, rs10888897, rs7552841, rs562556) proxied PCSK9 inhibition; 3 SNPs proxied
362 cholesterol-lowering in *LDLR* (rs6511720, rs1122608, rs688) (LDL-receptor inhibition).
363 Further details of these SNP effects are given in **Table 1**.

364

365 **Table 1.** Detailed summary of LDL-C lowering genetic variants in *HMGCR*, *NPC1L1*, *CETP*,
366 *PCSK9* and *LDLR* variants from the in Global Lipids Genetics Consortium (GLGC)

367

Target	SNP	Pathway	EA	OA	EAF	Beta	se	*P*-value
HMGCR	rs12916	LDL-C	T	C	0.57	-0.06061	0.003	7.79E-78
	rs17238484	LDL-C	G	T	0.75	-0.05184	0.005	1.35E-21
	rs5909	LDL-C	G	A	0.90	-0.05102	0.007	4.93E-13
	rs2303152	LDL-C	G	A	0.88	-0.03498	0.005	1.04E-09
	rs10066707	LDL-C	G	A	0.58	-0.0411	0.005	2.97E-19
	rs2006760*	LDL-C	C	G	0.81	-0.04407	0.006	1.67E-13
NPC1L1	rs217386	LDL-C	A	G	0.41	-0.02908	0.003	1.20E-19
	rs2073547	LDL-C	A	G	0.81	-0.03885	0.004	1.92E-21
	rs7791240	LDL-C	T	C	0.91	-0.03404	0.005	1.84E-10
	rs10234070	LDL-C	C	T	0.90	-0.02363	0.005	1.52E-06
	rs2300414	LDL-C	G	A	0.93	-0.02828	0.006	5.45E-06
CETP	rs3764261	LDL-C	A	C	0.29	-0.04471	0.004	2.22E-34
	rs1800775	LDL-C	A	C	0.48	-0.03487	0.003	8.54E-24
	rs1864163	LDL-C	G	A	0.73	-0.03698	0.004	7.97E-21

	rs9929488*	LDL-C	G	C	0.70	-0.03159	0.004	8.15E-13
	rs9989419	LDL-C	G	A	0.60	-0.02344	0.004	2.49E-12
	rs12708967	LDL-C	T	C	0.80	-0.02963	0.004	3.47E-11
	rs289714	LDL-C	A	G	0.79	-0.03032	0.005	2.85E-10
	rs5880*	LDL-C	G	C	0.94	-0.03979	0.008	1.59E-06
PCSK9	rs11206510	LDL-C	C	T	0.15	-0.06871	0.001	2.38E-53
	rs2479409	LDL-C	A	G	0.67	-0.05309	0.001	2.52E-50
	rs2149041*	LDL-C	C	G	0.84	-0.05259	0.001	1.44E-35
	rs2479394	LDL-C	A	G	0.72	-0.03192	0.001	1.58E-19
	rs10888897	LDL-C	T	C	0.40	-0.04192	0.001	8.43E-31
	rs7552841	LDL-C	C	T	0.63	-0.04589	0.001	5.40E-15
	rs562556	LDL-C	G	A	0.19	-0.05292	0.002	6.16E-21
LDLR	rs6511720	LDL-C	T	G	0.11	-0.17482	0.004	3.69E-54
	rs1122608	LDL-C	T	G	0.23	-0.05473	0.003	2.02E-86
	rs688	LDL-C	C	T	0.56	-0.04465	0.003	3.04E-48

EA, effect allele or low-density lipoprotein-cholesterol (LDL-C) lowering allele; OA = other or non-effect allele; EAF, effect allele frequency; se= standard error. * Palindromic SNPs removed

Beta represents the change in LDL-C levels per copy of the effect allele. For SI conversion of mmol/L to mg/dL, multiply by 38.7.

There was limited evidence of an effect of genetically-proxied inhibition of HMGCR and NPC1L1 on combined OC and OPC risk (OR IVW 1.1; 95%CI 0.6, 1.9, p= 0.82 and 1.0; 95% CI 0.4, 2.7, p= 0.99), respectively. (**Table 2** and **S1 Fig**). A similar result was found for genetically-proxied LDL-C lowering inhibition of CETP on OC and OPC combined (OR IVW 1.3; 95%CI 0.6, 2.6, p= 0.49) (**Table 2 and S1 Fig**). However, higher risk of combined OC and OPC was found in relation to genetically-proxied PCSK9 inhibition, equivalent to a 1 mmol/L (38.7 mg/dL) reduction in LDL-C (OR IVW 2.1; 95%CI 1.2, 3.4, p= 0.01; **Table 2 and Fig 1**). This is in contrast to the reduction in odds seen in relation to cardiovascular disease using the same instrument (OR IVW 0.6; 95%CI 0.4, 0.8, p <1 x10^{-03}; **Fig 2**) in 60,801 cases and 123,504 control subjects enrolled in the CARDIoGRAM consortia studies [38]. There was also some evidence that LDLR variants, resulting in genetically-proxied reduction in LDL-C equivalent to

a 1 mmol/L (38.7 mg/dL), reduced the risk of combined OC and OPC (OR IVW; 0.7; 95%CI 0.4, 1.0, p= 0.05; **Table 2, Fig 1**).

Fig 1. Forest plot showing the causal effects of *HMGCR*, *NPC1L1, CETP, PCSK9* and *LDLR* variants on the oral and oropharyngeal cancer subsites in GAME-ON. Effect estimates on oral and oropharyngeal cancer are reported on the log odds scale.

Fig 2. Forest plots showing the causal effects of cholesterol-lowering PCSK9 and LDLR single nucleotide polymorphisms on coronary heart disease and combined oral/ oropharyngeal cancer in GAME-ON. Effect estimates on oral and oropharyngeal cancer are reported on the log odds scale.

Table 2. Mendelian randomization results of genetically-proxied inhibition of HMGCR, NPC1L1, CETP, PCSK9 and LDLR with risk of oral and oropharyngeal cancer including sensitivity analyses in GAME-ON

					IVW		Weighted median		Weighted mode		MR-Egger	
	Outcome	**Exposure/ Outcome dataset**	**Outcome N**	**Number of SNPs**	**OR (95%CI)**	**P**	**OR (95%CI)**	**P**	**OR (95%CI)**	**P**	**OR (95%CI)**	**P**
HMGCR	Oral/ Oropharyngeal cancer	GAME-ON/ GLGC	6,034	5	1.07 (0.62, 1.84)	0.82	1.20 (0.63, 2.28)	0.58	1.20 (0.57, 2.50)	0.66	1.33 (0.07, 26.58)	0.86
	Oral cancer	GAME-ON/ GLGC	2,990	5	1.49 (0.75, 2.96)	0.25	1.66 (0.73, 3.78)	0.23	1.69 (0.65, 4.42)	0.35	1.25 (0.03, 55.80)	0.91
	Oropharyngeal cancer	GAME-ON/ GLGC	2,641	5	0.90 (0.43, 1.85)	0.77	1.01 (0.43, 2.34)	0.99	1.08 (0.44, 2.64)	0.88	0.77 (0.01, 45.07)	0.91
NPC1L1	Oral/ Oropharyngeal cancer	GAME-ON/ GLGC	6,034	5	1.01 (0.38, 2.69)	0.99	0.90 (0.29, 2.82)	0.86	0.86 (0.24, 3.08)	0.83	0.22 (0.00, 102.42)	0.66
	Oral cancer	GAME-ON/ GLGC	2,990	5	1.02 (0.30, 3.41)	0.98	1.20 (0.29, 5.05)	0.80	1.29 (0.22, 7.41)	0.79	0.09 (0.00, 160.66)	0.57
	Oropharyngeal cancer	GAME-ON/ GLGC	2,641	5	0.60 (0.16, 2.25)	0.45	0.60 (0.12, 3.04)	0.53	0.60 (0.10, 3.73)	0.62	0.20 (0.01, 688.64)	0.72
CETP	Oral/ Oropharyngeal cancer	GAME-ON/ GLGC	6,034	6	1.28 (0.64, 2.55)	0.49	1.24 (0.54, 2.81)	0.61	1.25 (0.43, 3.64)	0.71	0.82 (0.02, 27.60)	0.92
	Oral cancer	GAME-ON/ GLGC	2,990	6	1.65 (0.70, 3.88)	0.25	1.69 (0.61, 4.70)	0.31	1.63 (0.43, 5.87)	0.49	0.42 (0.01, 32.58)	0.72
	Oropharyngeal cancer	GAME-ON/ GLGC	2,641	6	1.12 (0.45, 2.77)	0.81	1.05 (0.35, 3.20)	0.93	0.73 (0.17, 3.07)	0.69	1.50 (0.02, 142.22)	0.87

PCSK9	Oral/ Oropharyngeal cancer	GAME-ON/ GLGC	6,034	6	2.05 (1.24, 3.38)	0.01	2.21 (1.12, 4.08)	0.01	2.19 (0.81, 5.92)	0.18	1.83 (0.17, 20.00)	0.65
	Oral cancer	GAME-ON/ GLGC	2,990	6	1.62 (0.89, 2.94)	0.11	1.80 (0.90, 3.62)	0.10	2.00 (0.73, 5.48)	0.23	2.17 (0.15, 32.13)	0.60
	Oropharyngeal cancer	GAME-ON/ GLGC	2,641	6	3.49 (1.58, 7.68)	2.00 E-03	3.19 (1.40, 7.26)	0.01	2.73 (0.86, 8.70)	0.15	1.99 (0.04, 92.11)	0.74
LDLR	Oral/ Oropharyngeal cancer	GAME-ON/ GLGC	6,034	3	0.65 (0.42, 1.00)	0.05	0.71 (0.47, 1.08)	0.11	0.74 (0.47, 1.15)	0.31	0.90 (0.41, 1.95)	0.83
	Oral cancer	GAME-ON/ GLGC	2,990	3	0.53 (0.32, 0.87)	0.01	0.56 (0.32, 0.98)	0.04	0.57 (0.32, 1.04)	0.21	0.56 (0.18, 1.76)	0.50
	Oropharyngeal cancer	GAME-ON/ GLGC	2,641	3	0.90 (0.53, 1.52)	0.69	0.91 (0.55, 1.53)	0.73	1.08 (0.62, 1.89)	0.81	1.56 (0.64, 3.82)	0.51

Abbreviations: IVW, inverse variance weighted; OR, odds ratio; CI, confidence intervals; P, *p*-value.

OR represents the exponential change in odds of oral/ oropharyngeal squamous cell carcinoma per genetically-proxied inhibition of drug target equivalent to a 1 mmol/L decrease in LDL-C.

Stratification by cancer subsite in GAME-ON. When stratified by subsite, the adverse effect of PCSK9 appeared to be mainly in the oropharynx, (OR IVW 3.5; 95%CI 1.6, 7.7, p= 2 x10^{-03}), with limited evidence in the oral cavity (OR IVW 1.6; 0.9, 2.94, p= 0.11) (**Table 2 & Fig 1**). The effects appeared stronger in OPC versus OC, but with overlapping confidence intervals. LDLR was associated with a reduction in risk of OC (OR IVW 0.5; 95%CI 0.3, 0.9, p= 0.01), but there was little evidence of an association with OPC (OR IVW 0.9; 95%CI 0.5, 1.5, p= 0.69) (**Table 2 and Fig 1**). For both PCSK9 and LDLR associations, the direction of effect was generally consistent across the four MR methods tested (**Table 2**).

Secondary analysis in GAME-ON. SNPs were also used to proxy circulating levels of LDL-C (77 SNPs), high-density lipoprotein cholesterol (HDL-C) (85 SNPs), total triglyceride (54 SNPs), total cholesterol (82 SNPs), apolipoprotein A (9 SNPs) and apolipoprotein B (14 SNPs) (**S1 Table**). There was limited evidence of an effect of any of these other lipid traits on either OC or OPC (**Table 3 and S2 Fig**).

437 **Table 3.** Mendelian randomization results of circulating lipid traits with risk of oral and

438 oropharyngeal cancer in GAME-ON

Target	N SNPs	Outcome	IVW OR (95% CI)	*P*-value
LDL-C	77	Oral/ Oropharyngeal cancer	0.98 (0.87, 1.11)	0.79
		Oral cancer	0.99 (0.85, 1.15)	0.88
		Oropharyngeal cancer	1.03 (0.87, 1.21)	0.76
HDL-C	85	Oral/ Oropharyngeal cancer	0.98 (0.83, 1.16)	0.79
		Oral cancer	1.08 (0.88, 1.32)	0.45
		Oropharyngeal cancer	0.87 (0.71, 1.05)	0.15
Total triglycerides	54	Oral/ Oropharyngeal cancer	1.19 (1.01, 1.04)	0.04
		Oral cancer	1.19 (0.96, 1.46)	0.11
		Oropharyngeal cancer	1.19 (0.96, 1.47)	0.12
Total cholesterol	82	Oral/ Oropharyngeal cancer	1.04 (0.91, 1.18)	0.55
		Oral cancer	1.09 (0.93, 1.28)	0.30
		Oropharyngeal cancer	1.00 (0.84, 1.20)	0.96
Apolipoprotein A	9	Oral/ Oropharyngeal cancer	0.87 (0.73, 1.03)	0.11
		Oral cancer	0.90 (0.73, 1.12)	0.34
		Oropharyngeal cancer	0.82 (0.65, 1.04)	0.10
Apolipoprotein B	14	Oral/ Oropharyngeal cancer	1.04 (0.88, 1.22)	0.67
		Oral cancer	1.15 (0.89, 1.49)	0.29
		Oropharyngeal cancer	1.00 (0.83, 1.21)	0.98

439

440 Abbreviations: IVW, inverse variance weighted; OR, odds ratio; CI, confidence intervals.

441 IVW OR represents the exponential change in odds of oral/ oropharyngeal squamous cell carcinoma
442 per SD increase in the circulating lipid trait (one SD for LDL-C = 38.7 mg/dL, HDL-C = 15.5 mg/dL,
443 Apolipoprotein A = 0.32 g/L, Apolipoprotein B = 0.52 g/L, Total triglycerides = 90.7 mg/dL, Total
444 cholesterol = 41.8 mg/dL).

445 **Sensitivity analyses.** IVW, MR Egger, weighted median, simple and weighted mode were
446 carried out, in addition to IVW analysis accounting for LD structure (**S2.1-2.5 Tables**). The
447 results adjusting for SNP correlation followed the same pattern as the main results (**S3**
448 **Table**). There was limited evidence of weak instrument bias being present (F-statistic >10)
449 and the proportion of variance in the phenotype (R^2) explained by the genetic instruments
450 ranged from 0.1 to 6% (**S4 Table**). In both primary and secondary analyses there was limited
451 evidence of heterogeneity in the SNP effect estimates for IVW and MR Egger regression,
452 except for in HDL-C (Q IVW 115.7, p= 0.01; Q MR Egger 115.6, p= 0.01) (**S5 and S6 Tables**).
453
454 MR Egger intercepts also indicated limited evidence of directional pleiotropy (**S7 and**
455 **S8 Tables**). For the primary analysis there were no clear outliers in both scatter and leave-
456 one-out plots (**Fig 3 and S3-6 Figs**) and MR-PRESSO detected no individual outliers (**S9**
457 **Table**). Where there was evidence of violation of the NOME assumption for the HMGCR,
458 NPC1L1 and CETP instruments (i.e. I^2 statistic <0.90) (**S10 Table**), MR-Egger was performed
459 with SIMEX correction and effects were still consistent with the null (**S11 Table**).
460
461 **Fig 3. Scatter plots for LDLR and PCSK9 single nucleotide polymorphisms effect on**
462 **combined oral/ oropharyngeal cancer in GAME-ON.**
463
464 **Replication in UK Biobank and meta-analysis of results.** Primary MR analyses as described
465 above were replicated in UK Biobank, showing limited evidence of an effect of genetically-
466 proxied inhibition of HMGCR, NPC1L1, CETP, PCSK9 and LDLR on risk of OC and OPC (**S12**
467 **Table**). Following IVW fixed-effects meta-analysis of GAME-ON and UK Biobank MR results,
468 there was a consistently strong effect of genetically-proxied PSCK9 inhibition on combined

469 OC and OPC (OR IVW 1.8; 95%CI 1.2, 2.8), with good concordance between studies (I^2= 22%)
470 and methods used (**Fig 4** and **S7 Fig**). Effects for PCSK9 appeared stronger in relation to OPC
471 (OR IVW 2.6; 95%CI 1.4, 4.9) than OC (OR IVW 1.4; 95%CI 0.8, 2.4), but with moderate
472 heterogeneity between studies (I^2= 41%) (**Fig 4**). Conversely, the protective effect for LDLR
473 on OC and OPC combined was also consistent in the meta-analysis (OR IVW 0.7; 95%CI 0.5,
474 1.0), with good concordance between studies (I^2= 0%) (**Fig 5** and **S7 Fig**). However, the
475 protective effect seen specifically in relation to OC in GAME-ON (OR IVW 0.5; 95%CI 0.3, 0.9)
476 was not replicated in UK Biobank (OR IVW 1.6; 95%CI 0.5, 4.8), with strong evidence of
477 heterogeneity between the studies (I^2= 66%).
478
479 **Fig 4. Forest plots showing inverse variance weighted meta-analysis effects of cholesterol-**
480 **lowering *PCSK9* single nucleotide polymorphisms on head and neck cancer subsites.**
481
482 **Fig 5. Forest plots showing inverse variance weighted meta-analysis effects of cholesterol-**
483 **lowering *LDLR* single nucleotide polymorphisms on head and neck cancer subsites.**
484
485 **Discussion**
486
487 We found limited evidence for a role of cholesterol-lowering in OC and OPC risk. This
488 included the absence of a protective effect of genetically-proxied inhibition of HMGCR,
489 suggesting previous observational studies investigating the relationship between statins and
490 head and neck cancer risk may be subject to residual confounding or bias. However, we did
491 observe an adverse effect of PCSK9 inhibition on OC and OPC risk, which was of a similar
492 magnitude to the protective effect seen in relation to cardiovascular disease using the same

493 genetic instrument (**Fig 2**). This PCSK9 effect was evident in both the GAME-ON (n= 6,034 OC
494 and OPC cases and n= 6,585 controls) and UK Biobank datasets (n= 839 OC and OPC cases
495 and n= 372,016 controls). We also found some evidence for a protective effect of
496 cholesterol-lowering variants in *LDLR* on OC and OPC risk in both studies. The IVW analysis
497 for HMGCR, NPC1L1, CETP, PCSK9 and LDLR accounting for LD structure (r^2<0.2) followed
498 the same pattern as the main results (**S3 Table**).
499
500 **Association between PCSK9, LDLR and cancer risk.** Despite the lack of consistent evidence
501 for a role of cholesterol-lowering on risk of OC or OPC in this study, individual effects of both
502 PCSK9 and LDLR were demonstrated which may implicate a role for these drug targets in the
503 development of OC or OPC via other mechanisms. The effects identified in the present study
504 are directionally consistent with a recent MR analysis of 1,615 combined head and neck
505 cancer cases from UK Biobank, which also found that a 1 SD unit increase in LDL-C proxied
506 by PCSK9 and LDLR was associated with a reduction (OR 0.7 95%CI 0.4, 1.4, p= 0.35) and
507 increase in odds (OR 1.6 95%CI 1.0, 2.4, p= 0.05) of head and neck cancer, respectively [29].
508 The opposing effects of PCSK9 and LDLR in this study also suggests that cholesterol lowering
509 is unlikely to be the main mechanism of action. However, this previous analysis is limited by
510 the relatively small number of cases and heterogeneity of head and neck cancer subtypes,
511 with no selection for the histological subtype of squamous cell carcinoma. In the present
512 study, we focused specifically on oral and oropharyngeal subtypes of HNSCC.
513
514 Beyond the established role of *PCSK9* in cholesterol homeostasis, other potential
515 pleiotropic effects are not well understood. Variants in *PCSK9* have been associated with an
516 increased risk of diabetes (OR 1.1, 95%CI 1.0, 1.2 for each 10 mg per decilitre decrease in

517 LDL-C) [28]. However, a recent phenome-wide association study (PheWAS) did not
518 find *PCSK9* or *LDLR* to be correlated with any non-lipid-related phenotypes, including
519 diabetes [49]. There is limited *in vivo* and *in vitro* evidence that *PCSK9* might be involved in
520 both cell proliferation and apoptosis. The gene was initially designated as NARC1 (neural
521 apoptosis-regulated convertase 1), involved in apoptosis of cerebellar neurons [50] and
522 *PCSK9* has since been found to be upregulated in some cancers [51, 52].
523
524 One suggested mechanism for a link with cancer progression is that the increased
525 expression of *PCSK9* prevents LDL-receptor (LDLR) recycling, leading to
526 hypercholesterolaemia and more exogenous lipid to support the proliferation of the tumour
527 [50]. Our study suggests the opposite, that genetically-proxied inhibition of *PCSK9* results in
528 an increased risk of OC or OPC. We hypothesise that access to intracellular LDL-C could in
529 fact be pro-tumourigenic, providing a favourable environment for a developing tumour cell,
530 maintaining membrane integrity and promoting cell division. Therapies such as statins,
531 ezetimibe, and PCSK9 inhibitors may all lower LDL-C level through the upregulation of LDL-
532 receptors, resulting in elevated intracellular cholesterol. However, cancer mechanisms are
533 often context dependent and perhaps only the expression of *PCSK9* and *LDLR* is relevant in
534 head and neck cancer. CETP inhibitors instead block the transfer of cholesteryl ester from
535 HDL-C to LDL-C, thereby raising HDL-C and lowering LDL-C (and apolipoprotein B), as well as
536 enhancing reverse cholesterol transport [53]. Unlike statins, CETP inhibitors do not appear
537 to increase the risk of type 2 diabetes, thought to be as a result of pancreatic islet cell
538 cholesterol accumulation with use of other cholesterol-lowering drugs [54]. Therefore, the
539 absence of effect when proxying *CETP* inhibition in this study, supports the possible
540 mechanism of LDL-C uptake via the LDL-receptor in OC or OPC.

While both *PCSK9* [55] and *LDLR* [56] are expressed in head and neck tumours, this was not evident in normal oral or oropharyngeal tissue, and sufficient tissue is currently not available in expression datasets [57]. Recent studies have associated elevated *PCSK9* with alcohol use disorder, including the interesting possibility of using anti-PSCK9 monoclonal antibodies for the treatment of alcoholic liver disease [58, 59]. Given that alcohol is a well-known risk factor for HNSCC, this pleiotropy could have partially explained the effect seen in our study, however we proxied the inhibition of *PCSK9* and so would have expected to see a protective effect of this gene in HNSCC cases who may have been heavy alcohol drinkers. Further investigation is required to untangle the relationship between *PCSK9*, alcohol and head and neck cancer.

Comparison with previous studies. It is believed that statins could play a potential role in cancer chemoprevention which may reduce the risk of some site-specific cancers such as prostate [60] and ovarian [30], but not all. Some of these studies have reported cancer risk reductions by as much as 50 – 65% [61-63]. However, meta-analyses and clinical trials have contradicted these findings [64, 65]. In addition to confounding, immortal time bias likely inflated observational results because, to be classified as a long-term statin user necessitates that users survived without cancer over a long period [19, 66]. Dickerman et al. used electronic records from 733,804 adults with 10-year follow-up to emulate a trial design. To achieve this a pre-specified protocol was set, including eligibility criteria and checks were made to ensure effect estimates for statins on cancer were comparable between the large observational dataset and trial. The authors found little indication that statin therapy influences cancer incidence, which was consistent with the analyses of

565 randomised trials (with a 10-year cancer-free survival difference of −0.3% 95%CI −1.5%,
566 0.5%) [19]. Nonetheless, recent MR studies [29, 30] have identified an association between
567 variants in *HMGCR* with cancer risk, but not alternative cholesterol-lowering treatments or
568 genetically-predicted LDL-C, suggesting that statins may reduce cancer risk through a
569 cholesterol independent pathway. A recent case-control study of over 11,000 participants
570 found an inverse association between statin use and the occurrence of HNSCC (OR 0.86,
571 95%CI 0.77, 0.95, p= <0.01, of prior statin exposure for cases compared to propensity
572 score-matched controls) [18]. However, a wider systematic review found that the evidence
573 for the role of statins in the prevention of HNSCC was limited [67]. As HNSCC incidence is a
574 rare outcome, randomised controls trials are not feasible, so we must be cautious
575 interpreting the available observational findings given the potential for bias and
576 confounding as discussed previously.
577
578 In contrast to previous MR studies assessing overall cancer risk [29] and ovarian
579 specific risk [30], the MR carried out here in relation to OC and OPC showed no effect using
580 genetic instruments for HMGCR (statins). There was also limited evidence for a causal effect
581 of NPC1L1 (ezetimibe), CETP (CETP inhibitors) as well as a number of other circulating lipid
582 traits on OC or OPC. Therefore, it remains unclear as to whether the effects observed with
583 PCSK9 and LDLR are via LDL-C lowering or another less well-established pathway [68, 69],
584 such as receptor regulation for viral entry, synthesis of sex hormones and resultant
585 dysregulated metabolism [70-72].
586
587 **Strengths and limitations of this study.** Protective associations between cholesterol-
588 lowering therapies such as statins and head and neck cancer risk seen in previous

observational studies could be a result of reverse causation, immortal time bias, lack of randomisation or confounding by socioeconomic status, smoking or HPV infection, for example. Our study applied MR in an attempt to overcome these issues, using the largest number of SNPs identified from the latest GWAS for both cholesterol-lowering and head and neck cancer that could be identified in the literature [25, 34]. A series of pleiotropy-robust MR methods and outlier detection were applied to rigorously explore the possibility that findings were not biased as a result of pleiotropy. However, there was no HPV data available in these summary results to enable more detailed stratified analysis of OPC. We did replicate findings for PCSK9 and LDLR, but the number of cases are low. Finally, most participants in the GAME-ON network [34] were of European or North American decent, with only around 11% from South America, and participants included in the UK Biobank analysis were exclusively of European descent, so more work is required to determine if our results translate to other ancestry groups.

In conclusion, our MR analyses provided little evidence for a role of cholesterol lowering in OC or OPC risk although effects of genetically-proxied inhibition of *PCSK9* and cholesterol-lowering variants in *LDLR* were observed in relation to OPC and OC risk. Given the lack of a common pathway to carcinogenesis in OC or OPC, metabolic targets that may be common to all tumours, regardless of the activated molecular pathway, could help simplify a preventative or therapeutic approach [73]. Replication of our findings in other head and neck cancer datasets and use of individual-level follow-up data with HPV status could provide further insight into the effect of these genetic instruments on risk, treatment outcomes and survival in head and neck cancer. With more evidence, future randomised

control trials could focus on treating high risk OC or OPC groups, such as those with severe dysplasia or who are HPV-16 E6 positive, with cholesterol-lowering therapies.

Data availability statement

Summary-level analysis was conducted using publicly available GWAS data [25, 33]. Full summary statistics for the GAME-ON GWAS can be accessed via dbGAP (OncoArray: Oral and Pharynx Cancer; study accession number: phs001202.v1.p1) [34]. Access to UK Biobank (https://www.ukbiobank.ac.uk/) data is available to researchers through application.

Code availability statement

Two-sample MR analyses were conducted using the "TwoSampleMR" package in R (version 3.5.3). A copy of the code used in this analysis will be made available at: https://github.com/rcrichmond/cholesterol_lowering_headandneckcancer

Acknowledgements

M.G. was a National Institute for Health Research (NIHR) academic clinical fellow and is currently supported by a Wellcome Trust GW4-Clinical Academic Training PhD Fellowship. This research was funded in part, by the Wellcome Trust [Grant number 220530/Z/20/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to

635 any Author Accepted Manuscript version arising from this submission. R.C.R. is a de Pass VC
636 research fellow at the University of Bristol. J.T. is supported by an Academy of Medical
637 Sciences (AMS) Springboard award, which is supported by the AMS, the Wellcome Trust,
638 Global Challenges Research Fund (GCRF), the Government Department of Business, Energy
639 and Industrial strategy, the British Heart Foundation and Diabetes UK (SBF004\1079).
640 R.M.M. was supported by a Cancer Research UK (C18281/A19169) programme grant (the
641 Integrative Cancer Epidemiology Programme) and is part of the Medical Research Council
642 Integrative Epidemiology Unit at the University of Bristol supported by the Medical Research
643 Council (MC_UU_12013/1, MC_UU_12013/2, and MC_UU_12013/3) and the University of
644 Bristol. JY is supported by a Cancer Research UK Population Research Postdoctoral
645 Fellowship (C68933/A28534). R.M.M. and A.R.N. are supported by the National Institute for
646 Health Research (NIHR) Bristol Biomedical Research Centre which is funded by the National
647 Institute for Health Research (NIHR) and is a partnership between University Hospitals
648 Bristol and Weston NHS Foundation Trust and the University of Bristol. This publication
649 presents data from the Head and Neck 5000 study. The study was a component of
650 independent research funded by the NIHR under its Programme Grants for Applied
651 Research scheme (RP-PG-0707-10034). The views expressed in this publication are those of
652 the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
653 Core funding was also provided through awards from Above and Beyond, University
654 Hospitals Bristol Research Capability Funding and the NIHR Senior Investigator award to
655 A.R.N. Human papillomavirus (HPV) serology was supported by a Cancer Research UK
656 Programme Grant, the Integrative Cancer Epidemiology Programme (grant number:
657 C18281/A19169). B.D. and the University of Pittsburgh head and neck cancer case-control
658 study are supported by US National Institutes of Health (NIH) grants: P50 CA097190, P30

CA047904 and R01 DE025712. The genotyping of the HNSCC cases and controls was performed at the Center for Inherited Disease Research (CIDR) and funded by the US National Institute of Dental and Craniofacial Research (NIDCR; 1X01HG007780-0). The University of North Caroline (UNC) CHANCE study was supported in part by the National Cancer Institute (R01-CA90731). E.E.V and D.L are supported by Diabetes UK (17/0005587). E.E.V is also supported by the World Cancer Research Fund (WCRF UK), as part of the World Cancer Research Fund International grant programme (IIG_2019_2009). E.H.T and P.S. were supported by the GENCAPO/FAPESP grant (10/51168-0).

Competing Interests

The authors declare no conflicts of interest. The funders had no role in the design of the study; the collection, analysis, and interpretation of the data; the writing of the manuscript; and the decision to submit the manuscript for publication. The authors alone are responsible for the views expressed in this article.

References

1. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45(4-5):309-16.

2. Saba NF, Goodman M, Ward K, Flowers C, Ramalingam S, Owonikoko T, et al. Gender and ethnic disparities in incidence and survival of squamous cell carcinoma of the oral tongue, base of tongue, and tonsils: a surveillance, epidemiology and end results program-based analysis. Oncology. 2011;81(1):12-20.

3. (CRUK) CRU. Head and neck cancer statistics 2019 [cited 2019 11/04/2019]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/head-and-neck-cancers#heading-Two.

4. Mehanna H, Kong A, Ahmed SK. Recurrent head and neck cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016;130(S2):S181-S90.

5. De Boer MF, McCormick LK, Pruyn JF, Ryckman RM, van den Borne BW. Physical and psychosocial correlates of head and neck cancer: a review of the literature. Otolaryngol Head Neck Surg. 1999;120(3):427-36.

700 6. Thomas SJ, Penfold CM, Waylen A, Ness AR. The changing aetiology of head and neck
701 squamous cell cancer: A tale of three cancers? Clin Otolaryngol. 2018;43(4):999-1003.

702 7. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human
703 papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med.
704 2010;363(1):24-35.

705 8. Elrefaey S, Massaro MA, Chiocca S, Chiesa F, Ansarin M. HPV in oropharyngeal
706 cancer: the basics to know in clinical practice. Acta Otorhinolaryngol Ital. 2014;34(5):299-
707 309.

708 9. Sleire L, Forde HE, Netland IA, Leiss L, Skeie BS, Enger PO. Drug repurposing in
709 cancer. Pharmacol Res. 2017;124:74-91.

710 10. Hu M, Cheung BM, Tomlinson B. Safety of statins: an update. Ther Adv Drug Saf.
711 2012;3(3):133-44.

712 11. Audi S, Burrage DR, Lonsdale DO, Pontefract S, Coleman JJ, Hitchings AW, et al. The
713 'top 100' drugs and classes in England: an updated 'starter formulary' for trainee
714 prescribers. British Journal of Clinical Pharmacology. 2018;84(11):2562-71.

715 12. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA
716 reductase. Science. 2001;292(5519):1160-4.

717 13. Ference BA, Kastelein JJP, Ginsberg HN, Chapman MJ, Nicholls SJ, Ray KK, et al.
718 Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein
719 Levels and Cardiovascular Risk. JAMA. 2017;318(10):947-56.

720 14. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin Use and Reduced Cancer-Related
721 Mortality. New Engl J Med. 2012;367(19):1792-802.

722 15. Mehibel M, Ortiz-Martinez F, Voelxen N, Boyers A, Chadwick A, Telfer BA, et al.
723 Statin-induced metabolic reprogramming in head and neck cancer: a biomarker for targeting
724 monocarboxylate transporters. Sci Rep. 2018;8(1):16804.

725 16. Chawda JG, Jain SS, Patel HR, Chaduvula N, Patel K. The relationship between serum
726 lipid levels and the risk of oral cancer. Indian J Med Paediatr Oncol. 2011;32(1):34-7.

727 17. Mehta R, Gurudath S, Dayansoor S, Pai A, Ganapathy KS. Serum lipid profile in
728 patients with oral cancer and oral precancerous conditions. Dent Res J (Isfahan).
729 2014;11(3):345-50.

730 18. Kao LT, Hung SH, Kao PF, Liu JC, Lin HC. Inverse association between statin use and
731 head and neck cancer: Population-based case-control study in Han population. Head Neck-J
732 Sci Spec. 2019;41(5):1193-8.

733 19. Dickerman BA, Garcia-Albeniz X, Logan RW, Denaxas S, Hernan MA. Avoidable flaws
734 in observational analyses: an application to statins and cancer. Nat Med. 2019;25(10):1601-
735 6.

736 20. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology
737 contribute to understanding environmental determinants of disease? Int J Epidemiol.
738 2003;32(1):1-22.

739 21. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal
740 inference in epidemiological studies. Hum Mol Genet. 2014;23(R1):R89-98.

741 22. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a
742 guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601.

743 23. Walker VM, Smith GD, Davies NM, Martin RM. Mendelian randomization: a novel
744 approach for the prediction of adverse drug events and drug repurposing opportunities. Int J
745 Epidemiol. 2017;46(6):2078-89.

746 24. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al.
747 Biological, clinical and population relevance of 95 loci for blood lipids. Nature.
748 2010;466(7307):707-13.

749 25. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al.
750 Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45(11):1274-+.

751 26. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-
752 density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic,
753 epidemiologic, and clinical studies. A consensus statement from the European
754 Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-72.

755 27. Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD. Effect of naturally random
756 allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease
757 mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian
758 randomization study. J Am Coll Cardiol. 2015;65(15):1552-61.

759 28. Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, et al.
760 Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. N Engl J
761 Med. 2016;375(22):2144-53.

762 29. Carter P, Vithayathil M, Kar S, Potluri R, Mason AM, Larsson SC, et al. Predicting the
763 effect of statins on cancer risk using genetic variants: a Mendelian randomization study in
764 UK Biobank. medRxiv. 2020:2020.02.28.20028902.

765 30. Yarmolinsky J, Bull CJ, Vincent EE, Robinson J, Walther A, Smith GD, et al. Association
766 Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian
767 Cancer. JAMA. 2020;323(7):646-55.

768 31. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-
769 specific haplotype structure and linking correlated alleles of possible functional variants.
770 Bioinformatics. 2015;31(21):3555-7.

771 32. Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, et al. Mendelian
772 Randomization Study of ACLY and Cardiovascular Disease. N Engl J Med. 2019;380(11):1033-
773 42.

774 33. Kettunen J, Demirkan A, Wurtz P, Draisma HH, Haller T, Rawal R, et al. Genome-wide
775 study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA.
776 Nat Commun. 2016;7:11122.

777 34. Lesseur C, Diergaarde B, Olshan AF, Wunsch V, Ness AR, Liu G, et al. Genome-wide
778 association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer.
779 Nat Genet. 2016;48(12):1544-50.

780 35. Consortium O. Consortium launches genotyping effort. Cancer Discov.
781 2013;3(12):1321-2.

782 36. Dudding T, Johansson M, Thomas SJ, Brennan P, Martin RM, Timpson NJ. Assessing
783 the causal association between 25-hydroxyvitamin D and the risk of oral and oropharyngeal
784 cancer using Mendelian randomization. Int J Cancer. 2018;143(5):1029-36.

785 37. Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian
786 randomization studies. Int J Epidemiol. 2013;42(5):1497-501.

787 38. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive
788 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease.
789 Nat Genet. 2015;47(10):1121-30.

790 39. Hemani G, Bowden J, Smith GD. Evaluating the potential role of pleiotropy in
791 Mendelian randomization studies. Hum Mol Genet. 2018;27(R2):R195-R208.

792 40. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid
793 instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol.
794 2015;44(2):512-25.

795 41. Bowden J, Smith GD, Haycock PC, Burgess S. Consistent Estimation in Mendelian
796 Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet
797 Epidemiol. 2016;40(4):304-14.

798 42. Hartwig FP, Smith GD, Bowden J. Robust inference in summary data Mendelian
799 randomization via the zero modal pleiotropy assumption. Int J Epidemiol. 2017;46(6):1985-
800 98.

801 43. Bowden J, Del Greco MF, Minelli C, Smith GD, Sheehan NA, Thompson JR. Assessing
802 the suitability of summary data for two-sample Mendelian randomization analyses using
803 MR-Egger regression: the role of the I-2 statistic. Int J Epidemiol. 2016;45(6):1961-74.

804 44. Bowden J, Spiller W, Del Greco F, Sheehan N, Thompson J, Minelli C, et al. Improving
805 the visualization, interpretation and analysis of two-sample summary data Mendelian
806 randomization via the Radial plot and Radial regression. Int J Epidemiol. 2018;47(4):1264-78.

807 45. Verbanck M, Chen CY, Neale B, Do R. Publisher Correction: Detection of widespread
808 horizontal pleiotropy in causal relationships inferred from Mendelian randomization
809 between complex traits and diseases. Nat Genet. 2018;50(8):1196.

810 46. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. Genome-wide
811 genetic data on ~500,000 UK Biobank participants. bioRxiv. 2017:166298.

812 47. Schwarzer G. meta: an R package for metaanalysis. R News. 2007;7:40-5.

813 48. Higgins SG. Measuring inconsistency in metaanalyses. BMJ Br Med J. 2003;327:557-
814 60.

815 49. Safarova MS, Satterfield BA, Fan X, Austin EE, Ye Z, Bastarache L, et al. A phenome-
816 wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR. NPJ Genom
817 Med. 2019;4:3.

818 50. Stoekenbroek RM, Lambert G, Cariou B, Hovingh GK. Inhibiting PCSK9 - biology
819 beyond LDL control. Nat Rev Endocrinol. 2018;15(1):52-62.

820 51. Lee S, Zhang C, Liu Z, Klevstig M, Mukhopadhyay B, Bergentall M, et al. Network
821 analyses identify liver-specific targets for treating liver diseases. Mol Syst Biol.
822 2017;13(8):938.

823 52. Marimuthu A, Subbannayya Y, Sahasrabuddhe NA, Balakrishnan L, Syed N, Sekhar
824 NR, et al. SILAC-based quantitative proteomic analysis of gastric cancer secretome.
825 Proteomics Clin Appl. 2013;7(5-6):355-66.

826 53. Dong B, Singh AB, Fung C, Kan K, Liu J. CETP inhibitors downregulate hepatic LDL
827 receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent
828 mechanism. Atherosclerosis. 2014;235(2):449-62.

829 54. Barter PJ, Cochran BJ, Rye KA. CETP inhibition, statins and diabetes. Atherosclerosis.
830 2018;278:143-6.

831 55. Atlas THP. PCKS9 2020 [Available from:
832 https://www.proteinatlas.org/ENSG00000169174-PCSK9/pathology.

833 56. Atlas THP. LDLR 2020 [Available from:
834 https://www.proteinatlas.org/ENSG00000130164-LDLR/pathology.

835 57. Atlas TH. LDLR Tissue 2020 [Available from:
836 https://www.proteinatlas.org/ENSG00000130164-LDLR/tissue.

837 58. Lee JS, Mukhopadhyay P, Matyas C, Trojnar E, Paloczi J, Yang YR, et al. PCSK9
838 inhibition as a novel therapeutic target for alcoholic liver disease. Scientific Reports.
839 2019;9(1):17167.

840 59. Lee JS, Rosoff D, Luo A, Longley M, Phillips M, Charlet K, et al. PCSK9 is Increased in
841 Cerebrospinal Fluid of Individuals With Alcohol Use Disorder. Alcoholism: Clinical and
842 Experimental Research. 2019;43(6):1163-9.

843 60. Wang K, Gerke TA, Chen X, Prosperi M. Association of statin use with risk of Gleason
844 score-specific prostate cancer: A hospital-based cohort study. Cancer Medicine.
845 2019;8(17):7399-407.

846 61. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, et al. Statins and
847 the risk of colorectal cancer. N Engl J Med. 2005;352(21):2184-92.

848 62. Khurana V, Bejjanki HR, Caldito G, Owens MW. Statins reduce the risk of lung cancer
849 in humans: a large case-control study of US veterans. Chest. 2007;131(5):1282-8.

850 63. Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A, et al. Statins
851 and prostate cancer risk: a case-control study. Am J Epidemiol. 2005;162(4):318-25.

852 64. Cholesterol Treatment Trialists C, Emberson JR, Kearney PM, Blackwell L, Newman C,
853 Reith C, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of
854 individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One.
855 2012;7(1):e29849.

856 65. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a
857 meta-analysis. JAMA. 2006;295(1):74-80.

858 66. Hernan MA, Sauer BC, Hernandez-Diaz S, Platt R, Shrier I. Specifying a target trial
859 prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin
860 Epidemiol. 2016;79:70-5.

861 67. Saka Herran C, Jane-Salas E, Estrugo Devesa A, Lopez-Lopez J. Protective effects of
862 metformin, statins and anti-inflammatory drugs on head and neck cancer: A systematic
863 review. Oral Oncol. 2018;85:68-81.

864 68. Dimitroulakos J, Marhin WH, Tokunaga J, Irish J, Gullane P, Penn LZ, et al. Microarray
865 and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas.
866 Neoplasia. 2002;4(4):337-46.

867 69. Osmak M. Statins and cancer: current and future prospects. Cancer Lett.
868 2012;324(1):1-12.

869 70. Gallagher EJ, LeRoith D. Obesity and Diabetes: The Increased Risk of Cancer and
870 Cancer-Related Mortality. Physiol Rev. 2015;95(3):727-48.

871 71. Joost HG. Diabetes and cancer: Epidemiology and potential mechanisms. Diabetes
872 Vasc Dis Re. 2014;11(6):390-4.

873 72. Hursting SD, DiGiovanni J, Dannenberg AJ, Azrad M, LeRoith D, Demark-Wahnefried
874 W, et al. Obesity, Energy Balance, and Cancer: New Opportunities for Prevention. Cancer
875 Prev Res. 2012;5(11):1260-72.

876 73. Bhat M, Skill N, Marcus V, Deschenes M, Tan X, Bouteaud J, et al. Decreased PCSK9
877 expression in human hepatocellular carcinoma. BMC Gastroenterol. 2015;15:176.

878

879

880

881

Fig 1. Forest plot showing the causal effects of *HMGCR*, *NPC1L1, CETP, PCSK9* and *LDLR* variants on the oral and oropharyngeal cancer subsites in GAME-ON.



Effect estimates on oral and oropharyngeal cancer are reported on the log odds scale.



Effect estimates on oral and oropharyngeal cancer are reported on the log odds scale.

Fig 2. Forest plots showing the causal effects of cholesterol-lowering *PCSK9* and *LDLR* single nucleotide polymorphisms on coronary heart disease and combined oral/ oropharyngeal cancer in GAME-ON.



Effect estimates on oral and oropharyngeal cancer are reported on the log odds scale.

Fig 3. Scatter plots for *LDLR* and PCSK9 single nucleotide polymorphisms effect on combined oral/ oropharyngeal cancer in GAME-ON.



Fig 4. Forest plots showing inverse variance weighted meta-analysis effects of cholesterol-lowering *PCSK9* single nucleotide polymorphisms on head and neck cancer subsites .



Fig 5. Forest plots showing inverse variance weighted meta-analysis effects of cholesterol-lowering *LDLR* single nucleotide polymorphisms on head and neck cancer subsites